

14 Aug 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: what Amgen's \$3.7bn ChemoCentryx buy means; Lilly's CEO on US drug pricing legislation; Pfizer's GBT acquisition; new data for Amgen's KRAS inhibitor combo; and a major China ADC alliance for Sanofi.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 12 August 2022, including: what [*Amgen, Inc.*](#)'s \$3.7bn [*ChemoCentryx, Inc.*](#) buy means; [*Eli Lilly and Company*](#)'s CEO on US drug pricing legislation; [*Pfizer Inc.*](#)'s [*Global Blood Therapeutics, Inc.*](#) acquisition; new data for Amgen's KRAS inhibitor combo; and a major China ADC alliance for [*Sanofi*](#).

This and all our other podcasts are available on the Pharma Intelligence channel on [*Apple Podcasts*](#), [*Google Podcasts*](#), [*SoundCloud*](#), [*TuneIn*](#) and [*Spotify Podcasts*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[*Amgen's \\$3.7bn ChemoCentryx Buy May Help Offset Growing Pains*](#)" - Scrip, 4 Aug, 2022.)

(Also see "[*As Lilly's Realized Sales Prices Drop, Ricks Reiterates Criticism Of US Drug Price Plan*](#)" - Scrip, 4 Aug, 2022.)

(Also see "[*Pfizer's Buying Spree Continues With GBT, Gaining A Sickle Cell Disease Franchise*](#)" - Scrip, 8 Aug, 2022.)

(Also see "[*Can Amgen Balance Efficacy, Safety With KRAS/PD-1 Combination?*](#)" - Scrip, 8 Aug,

2022.)

(Also see "[*Sanofi, Innovent Link On China Oncology Ambitions As ADCs Surge*](#)" - Scrip, 5 Aug, 2022.)

[*Click here to explore this interactive content online*](#) ✨